Kronos Bio appoints Deborah Knobelman as CFO and COO effective June 3, 2024

Kronos Bio, Inc.

Deborah Knobelman appointed CFO and COO, effective June 3, 2024, replacing Sandra Gardiner.
Knobelman previously served as CFO of Senti Biosciences (SNTI) from 2021 to May 2024.
Initial base salary $475,000; target annual bonus 40% of salary; signing bonus $50,000.
Equity grants: 246,390 stock options and 164,260 RSUs with graded vesting schedules.
She will receive severance benefits under the Company’s Severance Plan for qualifying terminations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Deborah Knobelman

Chief Financial Officer and Chief Operations Officer

Kronos Bio, Inc.

Effective: 2024-06-03
Filed: May 21, 2024, 7:59 PM ET

On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.

Departed

Sandra Gardiner

Chief Financial Officer

Kronos Bio, Inc.

Effective: 2024-06-03
Successor: Deborah Knobelman
Filed: May 21, 2024, 7:59 PM ET

On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deborah Knobelman was appointed as Chief Financial Officer and Chief Operations Officer at Kronos Bio, Inc..

Action: appointed
Role: Chief Financial Officer and Chief Operations Officer

Exact text from the filing

On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra Gardiner departed as Chief Financial Officer at Kronos Bio, Inc..

Action: replaced
Role: Chief Financial Officer

Exact text from the filing

On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001140361-24-026957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.